Gritstone bio, Inc. (GRTS)
After hours:
| Previous Close | 0.0621 |
| Open | 0.0630 |
| Bid | 0.0500 x 100 |
| Ask | 0.0555 x 100 |
| Day's Range | 0.0495 - 0.0645 |
| 52 Week Range | 0.0495 - 3.1700 |
| Volume | |
| Avg. Volume | 5,444,187 |
| Market Cap | 6.012M |
| Beta (5Y Monthly) | 0.50 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0900 |
| Earnings Date | Nov 06, 2024 - Nov 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.50 |
Business WireGritstone bio Takes Action to Preserve Value and Strengthen Capital Structure
EMERYVILLE, Calif., October 10, 2024--Gritstone bio, Inc. (Nasdaq: GRTS) ("Gritstone" or the "Company"), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced it has filed a voluntary petition under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware.
GlobeNewswireGritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer
--Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA subgroup where events accrue more slowly --21% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.79 [95% CI, 0.42-1.50])-- -- 38% relative risk reduction of progression or death with GRANITE vs. control in low ctDNA subgroup (HR=0.62 [95% CI, 0.23-1.70]) -- -- Strength of neoantigen specific
Simply Wall St.Gritstone bio Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Gritstone bio ( NASDAQ:GRTS ) Second Quarter 2024 Results Key Financial Results Revenue: US$921.0k (down 53% from 2Q...
